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Abstract 
 
Nelfinavir 1 has been found to be a very successful nonpeptidic HIV-protease inhibitor. 
 
According to a previous investigation, nelfinavir 1 proved to have an inhibitory effect on 
chymotrypsin-like activity of 20S proteasome. Previous studies also show the 
promotion of acceleration of the apoptosis process within cancer cells by inhibition of 
proteasome activity. Separate experiments proved nelfinavir 1 to be involved in the 
inhibition of Akt pathway – an enzymatic pathway that results in arrest of apoptosis and 
prolongation of cell survival, which is also a very common mechanism in many types of 
cancers. These characteristics made nelfinavir 1 a very promising target for the 
anticancer therapy development. In this project, the synthesis of two nelfinavir 1 
analogues was attempted, based on the replacement of the thiophenyl group by indole 
or phenyl group to give 2 and 3 respectively.  
 
 
The analogues were prepared in seven to eight steps from amino acids. Six of the 
synthesised compounds have been tested biologically following the MTS colourimetric 
assay procedure on THP-1 leukemia cells. 
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1. INTRODUCTION 
 
1.1. THE PROTEASOME 
 
In eukaryotes, archaea and some bacteria, proteasomes play a crucial role in destroying 
misfolded and superfluous proteins and producing cell cycle control modifying proteins 
by proteolysis in specific places. They are very large, multimeric protein complexes that 
are located in the nucleus and the cytoplasm of cells.1 The proteasomes that are present 
in eukaryotes and archaea are the 20S proteasomes. 20S is a proteolytic core unit, 
linked with two regulatory 19S pieces (placed on both sides of 20S) to build the whole 
26S complex.2 It has been examined in yeast that the 20S proteasome is a cylindrical 
particle, that contains in its structure two outer rings and two inner rings. These consist 
of 14 different subunits, which co-operate with each other. The outer rings are made of 
7 different α-subunits, with the inner rings consisting of 7 different subunits in each 
case with the exception of the β-type. β1, β2 and β5 subunits characterise the catalytic 
activity. All three are based on a similar mechanism but are distinguished according to 
their substrate specificity: trypsin-like, chymotrypsin-like and peptidyl-glutamyl 
peptide-hydrolyzing activity.3 The enzyme involved in the proteolysis process is 
dependent on the peptide residues that are to be cleaved. Trypsin preferably breaks 
amide bonds, where the carboxylic acid side of the peptide is lysine or arginine. 
Chymotrypsin performs proteolysis on peptides, which on the carboxylic end of the 
structure comprise amino acids containing aromatic side chains, phenylalanine, 
tryptophan and tyrosine. This feature ensures access of the peptide to the hydrophobic 
pocket of the enzyme. Finally, peptidyl-glutamyl peptide-hydrolyzing domain cleaves 
proteins ending with aspartic acid and glutamic acid on the carboxylic side. 
 2 
 
 
Figure 1 - Models of the 20S proteasome from Saccharomyces cerevisiae showing the α-β-β-α ring 
pattern (a) and the seven α-units in the outer ring (b).4 
 
The starting point of the protein digestion process is the attachment of ubiquitin - a 
small protein which itself consists of 76 amino acids. Looking deeper at the mechanism 
of ubiquitylation and targeting, it is an enzymatic process, where the C-terminal tail of 
glycine, from activated ubiquitin, binds  via an amide bond with the N-terminal tail of 
lysine residue which has been attached to the superfluous protein. This happens in a 
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three step process. First ubiquitin is activated, forming an active thioester by an 
ubiquitin-activating enzyme (E1). This reaction requires an energy supply, which comes 
from ATP hydrolysis. The next protein is carried to an ubiquitin-conjugating enzyme 
(E2), leaving E1. Finally one of many kinds of ubiquitin ligases (E3) catalyses 
translocation of ubiquitin to the lysine residue of the specific substrate.5 This tagged 
protein gives a signal to form a polyubiquitin chain by activating other ligases and 
adding the next ubiquitin units. This chain on the protein binds to 9 (out of 19) proteins 
that are incorporated in the 19S unit. The other 10 subunits of 19S bind to the outer 
ring in 20S. Protein degradation to requires binding of ATP to ATPase subunits, placed 
on 19S.6 This enables the protein to unfold and the ‘gate’ in the 20S to open. Thanks to 
this process, labelled protein can enter the narrow channels of the 20S core but also 
prevent uncontrolled crossing through this barrier and the degradation of cellular 
proteins. It is worth noting that all the ubiquitin proteins; after fulfilling their purpose, 
are recovered and reused in the next tagging process.7 To highlight the importance of 
ubiquitin protein function, those involved in the elucidation of the process were 
awarded the Nobel Prize for chemistry in 2004.1 
 
 
Scheme 1 - The attachment of ubiquitin to proteins for degradation by the proteasome.7 
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There are many cellular processes where the ubiquitination mechanism plays an 
important role. These include apoptosis, antigen processing or DNA transcription or 
repair.7 Cyclins, for example, are a group of proteins involved in cell development 
during the cell cycle and are also disregulated in many tumor cells. They are not 
enzymes themselves, but have an active site that activates cyclin-dependent kinase 
enzymes (Cdk).9 There are different types of cyclins controlling different stages of the 
cell cycle. To complete the process, those proteins have to be digested by proteasome, 
which is where the ubiquitin-proteasome system plays an important role.10 
Apoptosis is programmed cellular death which requires a supply of ATP, protein 
synthesis and gene transcription. It depends on the activity of caspases (group of 
cysteine proteases), p53 and p27 proteins, NF-B (protein complex used for the DNA 
transcription) and IB (inhibitors of NF-B).7 Later research showed the levels of 
ubiquitinated proteins increase while E1, E2 and E3 (enzymes involved in the 
ubiquitination process) levels decrease, prior to the completion of apoptosis. It has also 
been found that the ubiquitin-proteasome pathway destroys numerous important 
apoptosis proteins, some of which have been proven to have proteasome-inhibitory 
activity toward programmed cell death (which might have a major influence in tumor 
cell development). 
Proteasomes also have an impact on the immune system, being involved in the adaptive 
immune system. This is the system that allows the organism to have a stronger immune 
response by recognising pathogens by their specific antigens. These antigens are 
peptides that are produced by the proteasome in the process of degradation of proteins 
coming from pathogens attacking the organism.11 The proteasome also activates NF-B, 
an anti-apoptotic and pro-inflammatory factor, which makes it part of inflammatory and 
autoimmune diseases, such as systemic lupus erythematosus or rheumatoid arthritis.11  
There have been several proteasome inhibitors discovered to induce apoptosis, such as 
salinosporamide A (4), bortezomib (5) and MG132 (6) (Figure 2). 
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Figure 2 - Structures of the proteasome inhibitors: salinosparamide A (4), bortezomib (5), MG132 
(6) 
 
Salinosporamide A (4) is a novel marine natural product isolated from an extract of the 
marine bacterium Salinispora tropica. It is a potent and selective anticancer agent12  and 
inhibits proteasome activity through covalent bonding to the active site threonine 
residue of 26S (Scheme 2). Formation of a five-membered ring in the second step, 
blocks the approach of water, which prevents a breakdown of the inhibitor – 
proteasome complex.  
 
 
 
Scheme 2 – Mechanism of action for salinosporamide A (4) 
 
Bortezomib (5), marked as Velcade® is a dipeptide – Pyz-Phe-boroLeu with a boronic 
acid at the leucine residue instead of a carboxylic acid, and is used for relapsed multiple 
myeloma and mantle cell lymphoma treatment.13 It is the first proteasome inhibitor that 
has reached and successfully progressed through clinical trials.14 One principal activity 
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is to inhibit the breakdown of the NF-κB inhibitor IκB. A critical interaction of 
bortezomib 5 with the proteasome is its binding with the chymotryptic-like and the 
caspase-like active sites. The mechanism of action is based on the covalent linkage of 
the inhibitor’s boron atom with nucleophilic threonine and several hydrogen bonds 
between inhibitor and residues of the active site (Scheme 3). 
 
 
 
Scheme 3 – Interaction of bortezomib (5) with chymotryptic-like active site of the 20S proteasome 
 
MG132 (6) is an aldehyde proteasome inhibitor and reversibly forms a covalent bond to 
the threonine residue of the β subunit in the 26S proteasome (Scheme 4). It also inhibits 
NF-B activation by arresting proteolysis of their inhibitor IκB and has agonistic effects 
on JNK1 kinase that initiates apoptosis.15 
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Scheme 4 – Mechanism of action of MG132 (6)
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1.2. HIV-PROTEASE AND NELFINAVIR 
 
 Acquired Immunodeficiency Syndrome (AIDS) was first identified and reported by the 
US Center for Diseases Control (CDC) in1981 and only a few years later was discovered 
to be caused by the human immunodeficiency virus (HIV).16 As AIDS became a huge 
problem all over the world, finding antiviral therapies against HIV type 1 was of 
primary importance among many drug discovery research groups. By gaining 
knowledge about the virus’ life cycle, researchers could work on discovering drugs that 
would inhibit the effects of HIV in different stages of its life cycle.  
HIV is a member of the retrovirus group and its genetic information is presented in RNA 
form. It attacks T cells (cells belonging to a group of lymphocytes, important in many 
immunological processes) characterised by CD4 glycoprotein that is expressed on the T 
cell surface.17 In its life cycle, the virus first enters a cell and reverse-transcribes its RNA 
to DNA  via the reverse transcriptase enzyme (RT). In this form, the virus gets to the cell 
nucleus and there integrates with the genetic material of the infected cell, thanks to the 
integrase enzyme activity. The viral DNA is then transcribed to mRNA and transferred 
outside the nucleus to the cell cytoplasm, where it is translated into the viral proteins. 
Finally, the viral protein needs to divide into smaller, separate pieces, made possible by 
HIV protease that cleaves amide bonds and forms mature proteins. As a result, the cell is 
destroyed and releases new virions ready to infect other cells.18 
By developing further knowledge about the HIV life cycle, scientists have come up with 
some theories behind the prevention of AIDS. One such theory reflects the replication 
stage in virus life. These drugs inhibit the reverse transcriptase enzyme RT (for instance: 
AZT, ddI or nevirapine and delavirdine). Another strategy is based on the inhibition of 
HIV-protease, which prevents hydrolysis of polypeptide bonds to individual mature 
proteins (for example nelfinavir 1, ritonavir 7, saquinavir 8).19 
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Figure 3 - Structures of HIV-protease inhibitors: nelfinavir (1), ritonavir (7), saquinavir (8) 
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Figure 4 - Binding of nelfinavir 1 - in green - to HIV-1 protease, showing the C2-symmetric 
homodimer structure of the enzyme (a) and the secondary alcohol bound to the Asp-Thr-Gly 
region (cyan sticks, b). (PDB: 1OHR).20 
 
Kent and co-workers published the first crystal structure of HIV-protease. Analysis of 
the structure indicates it is a C2-symmetric homodimer with 99 amino acids in both 
subunits.21 There is also the specific amino acid sequence Asp-Thr-Gly in both 
monomers, which is characteristic of aspartic proteases.22 This amino acid triad is also a 
part of the two active sites of the enzyme, one on each monomer. 
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Proteases can be divided into two groups depending on the mechanism that activates 
their catalytic activity. In the first class of proteases amide bond hydrolysis is initiated 
by the nucleophilic atom on the amino acid side chain, which is first activated by 
another amino side chain. In the second class of enzymes, a nucleophile that attacks the 
carbonyl group on the amide bond is activated by water. The mechanism for water 
activation is, as of yet, not very well understood. It is known that the two active sites 
play an important role in this process, and studies prove that HIV-protease is one of the 
enzymes belonging to this class of proteases.18 
Nelfinavir 1 (formally AG1343 and marketed as Viracept®), as mentioned above, is one 
of the most successful HIV-protease inhibitors. It is an antiviral drug widely prescribed 
for the treatment of HIV infection used in combination with HIV reverse transcriptase 
inhibitors.23 It was approved for therapeutic use in 1997, and after only one year in the 
United States gained 30% of the market share, which is growing yearly.24 
 
 
Figure 5 – Nelfinavir precursor 9 
 
The discovery of nelfinavir 1 started from another compound 9 that showed tight 
binding with HIV-protease but its poor antiviral activity and poor water solubility made 
it an unattractive drug. According to previous results, the S-aryl substituent improves 
the inhibitory activity of the enzyme. Nelfinavir 1, an analogue of 9 with S-phenyl 
instead of S-naphthyl proved to be a potent inhibitor of HIV-protease. For a better 
understanding of the binding affinity, studies on the co-crystal structure of the 
nelfinavir complex with the protease were performed.25 The study showed that the S-
phenyl group of nelfinavir binds to the S1 pocket and has some additional interaction 
with the S3 pocket, with the decahydroisoquinoline occupies the S1’ hydrophobic 
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pocket and the tert-butylcarboxyamide residue occupies the S2’ region of the enzyme. 
The structure also proved that the 2-methyl-3-hydroxy-benzamide of the compound fits 
in the S2 pocket, where its 3-phenol group binds with the Asp-30 via hydrogen bonding, 
and the 2-methyl group interacts with two other amino acids Val-32 and Ile-84.26  
 
Figure 6 - Arrangement of nelfinavir 1 in the HIV-1 protease active site looking through the 
catalytic region (cyan ribbons) with labelled substrate pockets. (PDB: 1OHR).27 
 
Besides these two compounds, phenylalanine analogue 3 was also tested, showing much 
better binding affinity of nelfinavir 1 comparing to 3, making the former the lead 
compound.26 
 
Figure 7 – Nelfinavir analogue 2. 
It has been discovered that nelfinavir 1 causes several side effects, such as diarrhea, 
abdominal pain, flatulence and less commonly, excessive urination, fatigue, hepatitis 
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and rashes. It has also been found that it can inhibit the insulin degrading enzyme and 
block oral epithelial cell DNA synthesis.28,29 Despite these disadvantages, nelfinavir 1 
still remains one of the most effective and most widely used anti-HIV drugs. 
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1.3. NELFINAVIR AS A POTENTIAL ANTICANCER DRUG 
 
The approximate cost of a new cancer drug development is in the region of 1 billion 
dollars, with the time required to go from concept to Food and Drug Administration 
approval estimated to be around 15 years. One strategy to reduce the costs of this 
process is by repositioning molecules already approved for other indications.30 Making 
use of already available toxicity and pharmacokinetic data would then accelerate the 
progress of drug development.31 
During HIV resistance studies it has been found that the number of CD4 cells (co-
receptor, placed on the T cells, mainly attacked by HIV) increase even though the 
inhibitory activity of the antiretroviral drug had stopped due to acquired viral 
resistance. This observation suggested the possibility of HIV-protease inhibitors having 
effects on other enzymes.32 
During the late nineties, research groups examined mice infected with lymphocytic 
choriomeningitis virus and treated with ritonavir 7 (a HIV-protease inhibitor), to find if 
it caused effects other than that of its antiviral activity. As a result, they observed a 
significant inhibitory impact against antiviral cytotoxic T lymphocyte (CTL) activity by 
stopping the presentation of antigens on infected cells to CTL cells. This process causes 
incorrect activity of T lymphocyte cells,  which may contributing to AIDS therapies and 
other viral diseases.33 It has also been found throughout these studies that ritonavir 
inhibits the chymotrypsin-like activity of 20S proteasome, which at the same time 
caused massive growth of trypsin-like activity.33 Harbouring these interesting results, 
scientists extended the group of compounds tested in the same direction to other HIV-
protease inhibitors, among which N-acetyl-leucyl-leucyl-norleucinal (LLnL) 10 showed 
similar potency to ritonavir.34 Considering previous investigation in this area, which 
proved that proteasome inhibitors stop tumour growth by acceleration of the apoptosis 
process in cancerous cells only, scientists suggested that inhibition of proteasomes with 
protease inhibitors such as nelfinavir 1, is a very promising lead in the development of 
anticancer therapies. 
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Serine/threonine protein kinases called Akt are another factor crucial to the process of 
cell multiplication (making them involved in cancer development). Three different 
genes (Akt1, Akt2, Akt3) code for three different enzymes which are part of the non-
specific serine/threonine – protein kinase family and stop the apoptotic proccess.35 
Akt1 takes part in the pathway of cellular survival, and so by blocking apoptosis, these 
enzymes extend cell survival. As a result of this feature, Akt1 has been recognized as a 
key factor in many types of cancers. Inhibiting this enzyme may provide a pathway 
towards cancer treatment by facilitating apoptosis in cancer cells.35 
Scientists noticed that toxicities caused by HIV-protease inhibitors are similar to those 
observed in Akt inhibition, which led them to believe that HIV-protease inhibitors may 
be working in the same or a very similar way to Akt inhibitors. As mentioned before, the 
Akt enzymatic pathway is a common activity in many types of cancers and many 
researchers are working on developing anticancer agents based on the 
phoshphoinositode 3-kinase (PI3K)/Akt pathway. After several studies – screening six 
clinically approved HIV protease inhibitors, it has been found that three of them 
ritonavir 7, saquinavir 8 and nelfinavir 1 inhibited growth at clinical concentrations of 
the drug. From these results, we can see that the most effective was nelfinavir 1 and 
suggests its development as a prospective anticancer agent.36 
Studies made into the effects of 1, 7 and 8 on the basic level of Akt activation showed 
that nelfinavir 1 and saquinavir 8 decreased Akt phosphorylation. Other studies showed 
that nelfinavir can stop signalling to Akt from two types of tyrosine kinase receptors 
(IGF-IR and EGFR). Thus, it suggests that this HIV protease inhibitor is capable of acting 
at the level of the plasma membrane to inhibit growth factor receptor activation, which 
next inhibits the PI3K/Akt pathway.36 Nelfinavir was tested in a panel of drug-sensitive 
and drug-resistant breast cancer cell lines. All tested lines (with one exception) were 
inhibited by at least 60%. This research proved that 1 has activity against cancer cells 
that obtain resistance to therapies such as tamoxifen – which is another step toward 
successful anti-cancer therapy methodology.  
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2. AIMS 
 
Although nelfinavir is a successful antiviral drug, it has not been optimized for 
anticancer activity. It is likely that analogues of nelfinavir will be better than the parent 
molecule against this new indication. In order to study the structure – activity 
relationship (SAR) of nelfinavir 1 with the proteasome, the aim of this project is to 
synthesise a series of analogues and examine their biological activity.  
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3. RESULTS AND DISCUSSION 
 
2.1 THE PREVIOUS SYNTHESIS OF NELFINAVIR 
 
Looking at nelfinavir 1 retrosynthetically, this compound can be broken into three 
different elements: a perhydroisoquinoline derivative 13, a benzoic acid derivative 11 
and central 4-carbon core. 
There were many different synthetic routes for nelfinavir 1 published in the past two 
decades. In the first five disconnections presented below nelfinavir 1 is made from two 
main precursors: 3-hydroxy-2-methylbenzoic acid 11 (which can be synthesised from 
commercially available 3-amino-2-methylbenzoic acid 12 through diazotisation 
reaction) and amine 14 (Scheme 5). Although there were different methods published 
to obtain 14. Different research groups have investigated a variety of routes to find the 
best way for nelfinavir 1 synthesis (disconnection A – E) using these 
intermediates.1,37,38,39,40 
 
Scheme 5 – Retrosynthesis of nelfinavir to disconnections A, B, C, D and E. 
 
Disconnection A – One of the routes to synthesis intermediate epoxide was proposed by 
Tahashi Inaba.37 His work concentrated on making a general compound that can 
produce a number of protease inhibitors. The general method requires many 
regioselective protection and deprotection reactions, to assure that primary and 
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secondary hydroxyl groups react separately and with the correct stereochemistry. To 
afford the desired epoxide in the first step, amine 15 is protected with Cbz group and 
then treated with thiophenyl anion to produce the sulfide. Addition of HCl in MeOH 
removes the acetonide protection. Next protection of the primary hydroxyl group was 
performed with 4-nitrobenzoyl chloride (PNBCl) followed by treatment with MsCl to 
convert the secondary hydroxyl group to a leaving group. After basic treatment of such 
prepared product, PNB group is hydrolysed and spontaneous ring closure gives the 
epoxide, which then reacts with amine 13 giving desired fragment 14 (Scheme 6).37 
 
 
Scheme 6 – Retrosynthetic analysis of nelfinavir (1): Disconnection A. 
 
Disconnection B – This original method for nelfinavir 1 uses as a starting material N-
Cbz-L-serine 16. Reaction with sodium aryl thiolate gives the protected unnatural amino 
acid, which is converted to a chloroketone. This is reduced to the corresponding chloro 
alcohol by treatment with sodium borohydride. Lastly, alkali-initiated cyclisation of the 
alcohol gives the epoxide which then is opened by treatment with amine 13 forming 
desired fragment 14 (Scheme 7).1 
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Scheme 7 – Retrosynthetic analysis of nelfinavir (1): Disconnection B. 
 
Disconnection C – In this third method published by Rieger, L-serine 16 is also used as a 
starting material, like in the disconnection B.38 The amino acid is easily transformed to 
N-Cbz-S-phenyl-L-cysteine. Further formation of the  amineand addition of 2-lithio-1,3-
dithiane (made from 1,3-dithiane and n-BuLi) gives a ketone, which is reduced with 
sodium borohydride to provide the dithiane alcohol. To complete the synthesis of 
nelfinavir 1, the dithianyl group is removed to give α-hydroxy aldehyde, which can be 
aminated with 13 to achieve desired compound. By this method nelfinavir 1 is obtained 
by one step less than the previous route (Scheme 8).38 
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Scheme 8 - Retrosynthetic analysis of nelfinavir (1): Disconnection C. 
 
Disconnection D – This route requires D-tartaric acid 17 as a starting material. This is 
converted to acetonide diester, reduced and transformed into a dichlorodiol. After 
several protection and deprotection reactions, the protected amino alcohol is obtained, 
which upon reaction with sodium hydride forms desired aziridine. This functionality 
allows the addition of thiophenoxide by opening of the aziridine to create S-phenyl 
moiety with desired stereochemistry. This intermediate can be used for the synthesis of 
nelfinavir 1 by the deprotection of oxygen and formation of epoxide (Scheme 9).39 
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Scheme 9 – Retrosynthetic analysis of nelfinavir (1): Disconnection D. 
 
Disconnection E – This route uses sulfoxide as a starting material that undergoes 
stereoselective bromohydrin formation, which then can be converted to desired S-
phenyl derivative with a very good yield 82% (Scheme 10).40 
 
 
Scheme 10 – Retrosynthetic analysis of nelfinavir (1): Disconnection E. 
 
There are two published synthetic routes where thiophenyl group undergoes 
disconnection. In both cases it proceeds through the ring-opening of an aryl oxazoline 
and use of 3-acetoxy-2-methyl benzoyl chloride 18 - differently to most routes used by 
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other groups, where 3-hydroxy-2-methylbenzoic acid 11 was used, (Scheme 11 and 
12).41,42 
Disconnection F – In the work of Albizati et al., the starting material is again unnatural 
D-tartaric acid 17. This acid through seven straightforward protecting and deprotection 
steps forms a cyclic sulfate. The nitrogen nucleophile opens the cyclic sulfate giving 
directly the amino alcohol intermediate. Next epoxy-oxazoline is synthesised by 
addition of 3-acetoxy- 2-methylbenzoyl chloride 18. Epoxide ring is opened by 
introducing perhydroisoquinoline 13 and then ring-opening of an oxazoline by 
introduction of the thiophenol moiety. This gives the final product nelfinavir 1 (Scheme 
11).41 
 
 
Scheme 11 - Retrosynthetic analysis of nelfinavir (1): Disconnection F. 
 
Disconnection G – In this synthesis the required point is to synthesise amino alcohol, 
which is available from symmetric meso-epoxide 19 that is desymmetrised to afford 
azide, followed by reduction and hydrolysis. This prepared amino alcohol is treated 
with aryl acid chloride 18 forming amide and the desired oxazoline is obtained after 
cyclisation reaction on the amide. Following treatment of oxazoline with the 
perhydroisoquinoline 13 and then thiophenol group, gives nelfinavir 1 (Scheme 12).42 
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Scheme 12 – Retrosynthetic analysis of nelfinavir (1): Disconnection G. 
 
Disconnection H – One synthetic method presented as a last step reaction with 
decahydroisoquinoline 13, while the 3-hydroxy-2-methybenzoic acid moiety 11 was 
attached already. The group tried to obtain the required stereochemistry by attachment 
of amines to α,β-unsaturated sulfoxide 20, using the Michael addition reaction. Then 
reduction of sulfoxide to sulfide, coupling with 3-acetoxy-2-methybenzoic acid 21 and 
hydrolysis afforded the diol. Final treatment of this diol with tosyl chloride followed by 
coupling with the amine 13 gave nelfinavir 1 (Scheme 13).43 
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Scheme 13 – Retrosynthetic analysis of nelfinavir (1): Disconnection H. 
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3.2  APPROACH TOWARDS THE SYNTHESIS 
 
Most of the approaches described above to obtain nelfinavir suffered from a few 
drawbacks. These included the need for expensive reagents and starting materials, a 
complex synthesis which required numerous steps and reactions that are not fully 
controlled in terms of regio- and stereochemistry.40 Added to this, we required the 
replacement of the thiophenyl group with an indole and phenyl group in order to reach 
the desired targets 2 and 3. In this project, to replace the thiophenyl group of nelfinavir 
1 the two starting materials L-phenylalanine and L-tryptophan have been chosen 
considering the knowledge of the chymotrypsin-like activity. It is known that this 
enzyme in its active site has hydrophobic pocket where it binds to the particular amino 
acids phenylalanine and tryptophan which in their sidechain contain hydrophobic 
aromatic rings – phenyl and indole ring respectively. This transformation might 
increase the binding strength between compound and enzyme active site and increase 
the inhibitory effect compared to the nelfinavir 1. 
This change would be only a slight modification to most of the aforementioned 
syntheses but in others could be much more difficult. Upon consideration, it was 
decided that the most suitable method to achieve the desired targets is the one similar 
to the original epoxide-based route.1 It has proven before to be successful in the use of 
protected L-phenylalanine amino acid as a starting material, which would be crucial 
during the early stages of this work.  
In the aforementioned disconnection B (Scheme 7), diazomethane is used as one of the 
reagents.1 A big advantage of our chosen route by Wang and Nugent is that there is no 
need to use this chemical, as it is a highly hazardous toxic and explosive gas.44 They 
reported that activated N-Boc-protected amino acid L-phenylalanine 22, by treatment 
with 4-nitrophenol 23 provided Boc-L-phenylalanine–4-nitrophenol ester 24 that can 
then react with a sulfoxonium ylide, affording the dimethylsulfoxonium butylide 25, 
through nucleophilic attack.44 It has been shown reacting a product such as 25 with an 
acid chloride gives chloroketone 26. Using a bulky hydride donor they formed the 
desired anti-α-amino epoxide 27 with good yield and diastereoselectivity (Scheme 
14).44 
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Scheme 14 – Retrosynthesis of anti-α-amino epoxide 27 by Wang and Nugent and esterification of 
N-Boc-L-phenylalanine (22) with p-nitrophenol (23).44,57 
 
In order to prepare target compound 2, N-Boc-L-tryptophan amino acid 28 was to be 
used instead of N-Boc-L-phenylalanine 22.  
The epoxide can be then be opened with decahydroisoquinoline derivative 13 
(commercially available) that results in the formation of tertiary amine 33. Subsequent 
Boc removal with 4 M HCl in 1,4-dioxane affords the free amine 34 ready for final amide 
35 formation. This last step can proceed according to original work for nelfinavir 1 
coupling amine with acid 3-hydroxy-2-methylbenzoic acid 11 (Scheme 15).1 
 
As an idea for making a broad range of nelfinavir analogues, different amines and acids 
(or acid derivatives) other than decahydroisoquinoline derivative 13 and 3-hydroxy-2-
methylbenzoic acid 11 respectively can be used. 
The whole process can be divided into three stages; the synthesis of the anti- α-amino 
epoxide, the opening of the epoxide with different amines, and finally, the coupling of 
different acids to afford a variety of amides. 
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Scheme 15 – Proposed synthesis of nelfinavir analogue 2. 
 
The method used in this first step of the synthesis is an ester formation using DCC as a 
coupling reagent, which gave very good yield (scheme 16).44 The reaction mixture was 
allowed to stir for at least five times longer (7.5 h vs 1.5 h) than that reported in the 
paper, as after several trials it was found to give a better yieldConsidering the 
subsequent reactions and reagents which were to be used, an electron-withdrawing 
group such as Boc seemed to be the most suitable, as it needs acidic conditions to be 
removed. In this coupling, a by-product is produced: dicyclohexyl urea, which is an 
insoluble solid, removable by filtration.  
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Scheme 16 – Synthesis of the ester 29 
 
In the second step (Scheme 17), to prepare 30, trimethylsulfoxonium iodide is 
deprotonated in the presence of KOtBu in THF while refluxing for 2 hours producing 
dimethylsulfoxonium methylide.44 This intermediate, after being cooled, attacks the 
ester 29 to form, a  carbon – carbon bond, which is the key point to this reaction, as the 
mechanism indicates below. The product is a stable ylide while removal of co-product is 
accomplished by extraction with ethyl acetate (leaving excess nitrophenol from the 
previous step in the aqueous layer) and washing with distilled water, NaHCO3 and 
brine. Attempted purification by flash chromatography led to degradation of the 
product, so the product was used in the next step without further purification. The yield 
for this reaction is not very accurate due to impurities such as nitrophenol 23, difficult 
to remove completely by only extraction. 
 
 
Scheme 17 - Synthesis of the dimethylsulfoxonium 30 
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In the next step, the formation of chloroketone 31 (Scheme 18) by nucleophilic 
substitution was attempted. The hydrochloric acid treatment of dimethylsulfoxonium 
butylide 30 was supposed to form α-chloroketone 31 and as co-product DMSO.44 
However during this reaction our compound decomposed. The possible reason is that 
the literature method is based on phenylalanine whereas we have the electron rich 
indole ring present in tryptophan.44 This reaction failed to give desired product. 
 
 
Scheme 18 – Attempted synthesis of the chloroketone 31 
 
In accordance with this decision we decided to carry on this general idea for the project 
with a different amino acid as a starting material – phenylalanine 22. 
The first two steps (Scheme 19) proceeded in the same way as for the tryptophan 
compound, forming 24 and 25. After the first reaction to achieve the p-nitrophenyl 
ester, recrystallisation from ethanol was used to obtain pure compound.44  
 
 
 Scheme 19 – Synthesis of the ester 24 and the dimethylsulfoxonium ylide 25 
 
Unfortunately after the second step, compound 25 was impossible to purify completely 
and was used crude in the next reaction. Formation of α-chloroketone 26 (Scheme 20) 
by treatment of 25 with acid in this case was successful.44 To remove DMSO from the 
mixture extraction with ethyl acetate and hexane (1:2) and further washing with 
distilled water, NaHCO3 and brine were employed. The resulting product was 
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recrystallized from hot hexane.44 In the conversion of 25 to 26, similar acidic conditions 
used for Boc deprotection are employed, but in this case deprotection does not occur. It 
is probably because the chloroketone group is more reactive and the reaction is 
stopped right after completion, monitored by TLC, so that no further reactions can take 
place. Further Boc deprotection during this reaction might explain the low yield of this 
reaction. 
 
 
Scheme 20 – Synthesis of the chloroketone 26 
 
Then, the α-chloroketone was reduced to form epoxide 27 (Scheme 21) with a good 
yield (82%). Running this reaction with LiAl(OtBu)3H ensures high anti-selectivity, due 
to its bulky structure.  
 
 
Scheme 21 – Synthesis of the epoxide 27 
 
As the mechanism indicates, the reaction proceeds via formation of the intermediate 
chlorohydrin. Final epoxide-ring closure happens during work up with use of basic 
Rochelle salt solution. Substitution of this solution with water will result in obtaining 
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chlorohydrin intermediate.44 It is also important to use dry ethanol for this reaction as 
LiAl(OtBu)H forms hydroxides upon reaction with water.47 Also as this reagent is added 
dropwise, very slowly at -78 oC, ice can stop homogenous stirring and mixing of the 
reaction solution. In addition, Rochelle salt solution is used to break aluminium-
containing co-products to simplify work-up by extraction.44 
It is important to notice that this product is acid sensitive. It is impossible to purify it by 
flash column chromatography and it can only be purified by recrystallization. Yields 
obtained were similar to  those reported by Wang and Nugent.44 
Successful completion of the first stage of the project – having a substantial amount of 
desired epoxide compound 27, moved us to the second stage - the opening of the 
epoxide with different amines. This is a very good way to make a library of diverse 
analogues, as it gives us a wide variety of choices between different amines that could 
give us bigger spectrum of different biological results in the end. 
There were different methods used to synthesise 43 in previous publications. One of 
the original methods involves 8 hours of refluxing epoxide 27 and 
decahydroisoquinoline 13 solution in ethanol or 6 hours of reflux of the same 
substrates  in 2-propanol (Scheme 22).1,48 These reactions were performed though with 
a different protecting group attached to the amine – carboxybenzyl (Cbz). 
 
 
Scheme 22 – Previously published synthesis of 431, 48. 
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Initially, it had been decided to use: decahydroisoquinoline 13, benzylamine 35, 
morpholine 36, diethylamine 37 and L-proline methyl ester 38 to achieve respectively 
44, 39, 40, 41 and 42 (Scheme 23).  
 
 
 
Scheme 23 – The opening of epoxide 27 reactions with different amines 35, 36, 37, 38 and 13 
 
Work of R. T. Lum et al. on the synthesis of new potent inhibitors of the S20 proteasome 
has shown the C-terminal benzyl amide derivative of the non-selective, traditional 
serine protease inhibitor - ALLN (Ac-Leu-Leu-Nle-H), resulted in very selective 
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competitive inhibitors of the chymotrypsin-like activity of the 20 proteasome.49 This 
makes the choice of benzylamine 35 a suitable nucleophile for opening of the epoxide in 
this work. 
Different methods of the epoxide 27 opening were published in the literature. In work 
presenting the synthesis of the C2-symmetric aminodiol protease inhibitor drugs, 
solution of epoxide 27 and benzylamine 35 in acetonitrile was stirred with LiClO4 at 
room temperature for 22 hours.50 In my case, the reaction was not going to completion 
in the suggested time, and the reaction mixture was stirred for another 12 hours 
obtaining desired 39. The product did not require any further purification as it  
precipitatedduring quenching with distilled water. The yield obtained in this case was 
not as good as the one published in article (39% vs 96% respectively) but this might  
Happen because the recrystallization was not optimazed. 50 
To test the utility of this method used for benzylamine 35, it has been decided to 
perform three other reactions with amines 36, 37, and 38 following the same 
procedure. Synthesis of compound 40 and compound 41 were never attempted before 
to the best of our knowledge. Morpholine and diethylamine were stirred in acetonitrile 
with LiClO4. In both cases, a long reaction time (over 30 hours) was needed to bring the 
reaction to completion. (Scheme 23) The advantage is that no additional purification 
was needed for both compounds. Morpholine derivative 40 was simply collected by 
filtration, as the desired product 40 crashed out, in a pure form, from the reaction 
solution upon quenching with distilled water and a little addition of diethyl ether. 
Diethylamine derivative 41 also crashed out while quenching the reaction with distilled 
water, giving an off yellow solid. Yield of the reaction producing 41 can be considered as 
absolutely satisfactory – 88%. This cannot be said about morpholine derivative 40 with 
moderate yield – 33%. The other disadvantage is the excessive (5 equivalent) use of the 
required amines. To assure the highest yield of the reactions, five equivalents of each 
amine is required, which increases the cost of production. 
These three experiments, giving compounds 39, 40 and 41 proved to be successful for 
the epoxide ring opening reaction, with both primary and secondary amines. To keep 
cohesion in methodology and for simplification of the previously mentioned methods 
(Scheme 22) without need of reflux, the same procedure was used for N-Boc aminol 44 
synthesis (which also has never been attempted via this approach). To avoid 
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unnecessary use of very expensive secondary amine 13, only 1.5 equivalents were used 
in the reaction (Scheme 23). Also unreacted excess of amine 13 can be recovered from 
the mixture by flash column chromatography or by acidic extraction. This reaction gives 
fairly good yield – 51% of crude product but unfortunately only 16% yield of pure 
product after flash column chromatography. 
One more attempt was performed following the LiClO4 method, with L-proline methyl 
ester hydrochloride 38. As this ester is stored as a salt, it had to be neutralised using a 
base before the epoxide ring opening was then carried out. Surprisingly this trial did 
not give the expected product (Scheme 23). The reason for this failure could be the need 
for neutralisation of the ester 38 before putting the reagent to the reaction, while here 
it was attempted to be neutralised in the reaction solution by additional input of 1 
equivalent of base. This reaction was not repeated due to lack of time. 
Epoxide 27 ring opening reaction with benzylamine 35 (Scheme 23) gave aminol 39 
with a secondary amine. It is necessary to protect this amine before proceeding with 
deprotection of the Boc, to prevent undesired reactions in the following steps, by 
competition with free primary amine. To do so, acetylation of secondary amine group 
on a similar compound, reported, was repeated to obtain novel compound 45, with 
yield 44% (Scheme 24).51,86 
This compound can undergo deprotection reaction, however, due to a lack of time, this 
has not been done. 
 
 
Scheme 24 – Synthesis of the acetylated benzylamine derivative 45 
 
Boc is a stable protecting group toward most nucleophiles and bases, cleaveable under 
strongly acidic conditions, producing tert-butyl cation as a co-product. The most 
common ways for deprotection are the use of 4 M solution of HCl in 1,4-dioxane or 
trifluoroacetic acid (TFA).52,53 It has been shown before that deprotection through 
 35 
 
reflux very often leads to by-products with sensitive compounds, so it is more favoured 
to use methods that do not require heating. 
The method we used is a classic procedure for Boc-group deprotection used in many 
peptide syntheses.54 Protected amine is stirred with 4 M HCl solution in 1,4-dioxane 
until Boc group is entirely removed from the compound, as observed by TLC. Boc 
cleavage has been worked up in two ways. After completion of the reaction, mixture 
was evaporated and then co-evaporated with acetonitrile and chloroform, followed by 
basic extraction to neutralise the formed HCl salt to give the free amine. In the other 
approach, product after evaporation was put straight to the next reaction. This requires 
the addition of extra base in the next reaction in order to neutralise the formed salt and 
to enable the reaction to proceed. 
Reactions on the prepared compounds 40 and 41 were carried out according to the 
explained procedure, affording pure amines 46 and 47, with 80% and 79% yield 
respectively (Scheme 25).  
 
 
Scheme 25 – Deprotection reactions on compounds 40 and 41. 
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The final step of the synthesis was coupling of the deprotected aminols 46 and 47 with 
carboxylic acid derivatives. It has been chosen to use acetyl chloride and benzoyl 
chloride to complete these final steps. Unfortunately only one of them – the coupling of 
47 with benzoyl chloride gave the desired product 51, while three remaining reactions 
to produce 48, 49 and 50 failed (Scheme 26). 
 
Scheme 26 – Attemps to synthesis of nelfinavir analogues amides 48, 49, 50 and 51 
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Further steps on 44 were also attempted. N-Boc aminol 44 was deprotected in HCl 
conditions and straight after freeing the amine group from N-Boc protection (monitored 
by TLC), the coupling of amine 52 was attempted, also with acetyl chloride and benzoyl 
chloride. These two trials also didn’t seem to give any of desired compounds 53 and 54 
respectively (Scheme 27). 
 
Scheme 27 – Attemps to synthesis nelfinavir analogues amides 53 and 54 
 
Due to the pressure of time, no more syntheses were performed. Regarding all these 
reactions that did not happen to work and produce final amides, there are different 
methods that could be used to achieve desired compounds. Acyl chlorides and benzoyl 
chloride could be replaced with anhydride derivatives, for example acetic anhydride 
and benzoyl anhydride which are also very reactive reagents. All of them are unstable in 
presence of water, being hydrolysed to their carboxylic acids – acetic acid and benzoic 
acid respectively, which makes dry reaction conditions a priority. 
Also in original work for nelfinavir 1 the final step of amide formation is performed 
with the carboxylic acid 11 using DCC and 1-hydroxybenzotriazole hydrate (HOBt) as 
coupling reagents in DMF.1 For this work these conditions could be used also for the 
amide formation with acetic acid and benzoic acid giving more chances for the 
successful synthesis. 
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3.3   BIOLOGICAL TESTING OF NELFINAVIR ANALOGUES 
 
In medicinal chemistry and drug discovery, after identification of potential drug targets, 
synthesis and characterisation, biological assays for therapeutic efficacy take place. 
These are the experiments to assess the effect of the synthesised chemicals on the target 
and give information on the validity of the strategy used. 
To complete this project, an MTS colourimetric assay was performed using THP-1 
human leukemia cells. It is a proliferation assay to measure the number of viable cells 
after their interaction with applied compounds. The test is based on the bioreduction by 
cells of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] into formazan product, a coloured compound which is 
soluble in cell culture medium (Figure 8). For the clarity of this method the number of 
living cells in culture is directly proportional to the quantity of formazan product 
(measured by the absorbance).55 
 
 
 
Figure 8 - Structures of MTS tetrazolium and its formazan product. 
 
The results from the MTS assay showed that the morpholine derivative 40 and 
acetylated benzylamine derivative 45 have no anti-proliferative activity (>1 mM) in 
THP-1 cells. Moderate activity was found with benzylamine derivative 39, diethylamine 
derivative 41 and decahydroisoquinoline derivative 44, giving an IC50 of 34 µM, 37 µM 
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and 33 µM respectively. Interestingly the only compound without N-Boc protecting 
group tested in this assay showed the best result – 2.8 µM. This would appear to be a 
key characteristic in finding potent compounds in future work (Table 1). 
 
Compound Structure IC50 Compound Structure IC50 
 
 
 
39 
 
 
 
 
34 
µM 
 
 
 
44 
        
 
 
 
 
33 
µM 
 
 
40 
 
 
 
>1 
mM 
 
 
45 
        
 
>1 
mM 
 
 
41 
 
 
 
 
 
37 
µM 
 
 
47 
         
 
 
 
2.8 
µM 
 
Table 1 – Results of MTS assay – IC50 of compounds 39, 40, 41, 44, 45 and 47. 
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4. CONCLUSIONS 
 
A preliminary attempt to synthesise nelfinavir 1 derivative 2 failed during the early 
stages of the synthetic route. After successfully obtaining the first two products: 4-
nitrophenol ester 29 and dimethylsulfoxonium derivative 30, synthetic investigations 
to produce the chloroketone derivative 31 did not yield the desired product. This is 
possibly due to the substitution phenyl group with indole (Scheme 28).44 
 
 
 
Scheme 28 – Unsuccessful approach to Wang and Nugent method used for tryptophan-based 
analogue 2. 
 
The synthesis towards the second derivative of nelfinavir 1 – compound 3, proved this 
methodology to be more successful, finally forming the amide 51 (Scheme 29). The 
esterification reaction between phenylalanine 22 and p-nitrophenol 23 yielded the 
desired 4-nitrophenol ester 24, with a very pleasing yield of 97%. The next 3 steps, 
following the procedures suggested by Wang and Nugent, proved this method to be  
useful, giving the desired dimethylsulfoxonium derivative 25, chloroketone derivative 
26 and finally the epoxide 27, all with very satisfactory yields – 88%, 48% and 82% 
respectively.44 The next stage of the synthesis was the epoxide ring opening using 
different primary and secondary amines. All the attempted reactions were performed 
according to the same lithium perchlorate-mediated method, not used previously for 
this group of compounds.50 Out of the five trials, using the benzylamine 35, morpholine 
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36, diethylamine 37, L-proline methyl ester 38 and finally decahydroisoquinoline 
derivative 13, four gave the expected products, while that with 38 failed.  
 
 
 
Scheme 29 – Overall synthetic route for the formation of nelfinavir analogue 51. 
 
The protection of the secondary amine group of benzylamine derivative 39 was 
achieved with an acetylation reaction, giving novel compound in this synthesis.51 
Boc deprotection was successfully performed on compounds 40, 41 and 44, providing 
next novel compound 47 to the best of our knowledge in this work. 
For the final stage of this synthesis, six different coupling reactions between synthesised 
aminols 46, 47 and 52 and two carboxylic acid derivatives acetyl chloride and benzoyl 
chloride were performed. Unfortunately only one out of all six produced the expected 
product 51. Further methods were not attempted due to the lack of sufficient time. 
As a final study for this project, a biological assay was carried out on six synthesised 
compounds 39, 40, 41, 44, 45 and 47 (Figure 9).  TheMTS colourimetric assays on THP-
1 leukaemia cells, gave interesting results; especially for deprotected diethylamine 
derivative 47, showing its IC50 – 2.8 µM, which is a very promising outcome and places 
particular attention on developing this structure for  future work.  
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Figure 9 – Structures of compounds 39, 40, 41, 44, 45 and 47 tested biologically in MTS assay. 
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5. FUTURE PERSPECTIVES 
 
The final, unsuccessful stage of the synthesis performed in this work using two types of 
acyl chloride – the acetyl chloride and the benzoyl chloride, places importance on 
developing other methods to perform these reactions in future as they are the key point 
throughout the synthesis. Utilisation of different acid derivatives such as acid 
anhydrides, which are very reactive reagents, might bring the reaction to completion 
and yield the desired amides. Use of other methods for coupling carboxylic acids with 
the amine group, such as the application of dicyclohexylcarbodiimide (DCC) and 1-
hydroxybenzotriazole hydrate (HOBt) or benzotriazol-1-yl-oxytripyrrolidino-
phosphonium hexafluorophosphate (PyBOP) could give expected compounds in future. 
Also implementation of different carboxylic acids or acid derivatives would produce a 
more diverse range of compounds ready for screening.  
During the second stage of the synthesis – the epoxide ring opening – a wide range of 
different amines could be used to extend the variety of formed structures. Different 
alkyl, cyclic, aromatic or asymmetric amines as well as others with aromatic 
heterocycles, would be an excellent idea to broaden the library of nelfinavir 1 analogues. 
To protect the secondary amine group formed by the attachment of benzylamine 35 to 
the epoxide 27, an acetylation reaction was performed. This nitrogen could be also 
protected through methylation, producing another derivative. 
Different amino acids could also be employed in the first step of this synthesis, to widen 
the diversity of analogue compounds. Considering the existing knowledge of the 
proteasome structure it would be preferable to choose amino acids with a hydrophobic 
character such as isoleucine or leucine to increase the possibility of good interaction. 
The MTS assay on THP-1 cell line with six of the synthesised compounds in this project 
showed the most attractive results for the aminol 47, the only one having undergone N-
Boc deprotection. For this reason it would be interesting to do more tests on 
deprotected compounds. It also seems sensible to develop the synthesis of 47 for future 
biological tests, as the diethylamine attached instead of decahydroisoquinoline 
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derivative which would make the compound much smaller in molecular weight which is 
a desirable feature in drug discovery. As nelfinavir 1 has not been tested on this type of 
cell, it would be worthwhile to check its activity in this cell line for pure comparison and 
assessment of worthiness of the synthesis for the future continuation of drug discovery. 
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6. EXPERIMENTAL 
 
6.1   GENERAL EXPERIMENTAL 
 
The reagents and solvents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa 
Aesar and Novabiochem. The anhydrous solvents were bought from Aldrich as sure-seal 
bottles. Anhydrous THF was  freshly distilled from sodium. 
Reactions were monitored by thin layer chromatography (TLC) using pre-coated 
aluminium backed sheets of silica. The spots were visualised with UV light and a 
potassium permanganate stain. Column chromatography was carried out using silica gel 
(MN Kieselgel 60, 40-63 µm 230-400 mesh ASTM). 
Melting points were determined using an Electrothermal melting point apparatus. 
Optical rotation analysis was performed on a polarimeter Optical Rotation PolAAr 3001 
instrument or polarimeter ADP220 (Bellingham and Stanley) in HPLC grade methanol.  
Infrared spectra were recorded using a Thermo Nicolet 380 FT-IR spectrometer with a 
Smart Orbit Golden Gate attachment. Absorptions are reported in wavenumbers (cm-1).   
NMR spectra were taken on a Bruker AV-300 or Bruker DPX-400 instrument (300 or 
400 MHz 1H, 75 MHz 13C), in CDCl3 unless otherwise noted. The chemical shifts data  are 
reported in ppm. Multiplicity is described by: s, singlet; d, doublet; t, triplet; q, quartet; 
quin, quintet; m, multiplet; app., apparent; r, roofing and br, broad.  
Electrospray ionisation MS (ESI-MS)  was undertaken on a Micromass Platform II 
instrument with a quadropole detector, using acetonitrile as solvent.  
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6.2   EXPERIMENTAL 
 
(2S)-4-Nitrophenyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoate 
(29) 
 
 
 
To N–Boc–L–tryptophan 28 (2.29 g, 7.5 mmol, 1.0 eq.) in EtOAc (30 mL) was added p-
nitrophenol 23 (1.05 g, 7.5 mmol, 1.0 eq.) and dicyclohexyl carbodiimide (1.64 g, 7.9 
mmol, 1.1 eq.). The reaction mixture was stirred for 15 hours and then filtered through 
Celite. The resulting clear solution with added hexane (55 mL) was washed sequentially 
with water (30 mL), NaHCO3 solution (30 mL x 3) and brine (30 mL x 3), dried over 
MgSO4, filtered and concentrated in vacuo. The resulting solid was azeotroped from 
chloroform, yielding 29 as a pale yellow solid (2.38 g, 75%). 
 
1H NMR (300 MHz, CDCl3) δ 1.46 (9H, s), 3.33-3.54 (1H, m), 4.87 (1H, d, J = 6.6 Hz), 
5.18 (1H, d, J = 7.0 Hz), 7.01 (2H, d, J = 1.0 Hz), 7.09-7.19 (2H, m), 7.21-7.26 (1H, m), 7.42 
(1H, d, J = 8.1 Hz), 7.61 (1H, d, J = 8.1 Hz), 8.19 (2H, d, J = 9.1 Hz), 8.24 (1H, br s). 
The spectroscopic data are consistent with that reported in the literature.56 
 
 
 
 
 
 47 
 
(3S)-Tert-butyl (4-(dimethylsulfoxonium)-1-(1H-indol-3-yl)-3-oxobutan-2-
yl)carbamate (30) 
 
 
 
A 250 mL round bottom flask was charged with trimethyl sulfoxonium iodide (4.20 g, 
19.2 mmol, 3.0 eq.) in anhydrous THF (11 mL) under a nitrogen atmosphere. To this, a 
solution of potassium tert – butoxide (2.15 g, 19.2 mmol. 3.0 eq.) dissolved in 11 mL of 
anhydrous THF was added. The flask was equipped with a condenser and heated to 70 
oC for 2 hours. The solution was then cooled to 0 oC. Boc–L–Trp–4–nitrophenol 29 (2.72 
g, 6.4 mmol, 1.0 eq.) in 7 mL of anhydrous THF was added dropwise to the cooled 
mixture over 15 min and allowed to stir for another hour. Then distilled water was 
added and stirred for a further 15 min and the solution was brought to room 
temperature. After filtration through Celite, the filtrate was concentrated in vacuo. The 
residue was next rinsed with distilled water (15 mL) and extracted with EtOAc (15 mL 
and 2 x 7 mL). The organic extract was washed with distilled water (2 x 5 mL), followed 
by NaHCO3 solution (4 x 5 mL) and brine (4 x 5 mL) and concentrated in vacuo. The 
resulting solid was azeotroped from chloroform to yield 30 as yellow solid (1.43 g, 
59%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 1.43 (s, 9 H), 3.04 (s, 1 H), 3.10 - 3.30 (m, 1 H), 3.22 
(s, 1 H), 3.47 (s, 1 H), 4.38 (m, J=7.7 Hz, 1 H), 4.32 (s, 1 H), 5.36 (d, J=8.1 Hz, 1 H), 7.00 - 
7.10 (m, 2 H), 7.15 (t, J=7.7 Hz, 1 H), 7.30 - 7.37 (m, 1 H), 7.63 (d, J=8.1 Hz, 1 H), 8.34 (br. 
s., 2 H). 
The spectroscopic data are consistent with that reported in the literature.56 
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(2S)-Tert-butyl (4-chloro-1-(1H-indol-3-yl)-3-oxobutan-2-yl)carbamate (31) 
 
 
 
In a 100 mL round bottom flask under nitrogen, were placed compound 30 (1.42 g, 3.8 
mmol, 1.0 eq.) and THF (25 mL). A solution of hydrochloric acid in 1,4-dioxane (4.0 M, 
0.62 mL, 4.4 mmol, 1.2 eq.) – was added dropwise over 5 minutes. The mixture was then 
allowed to reflux (70 oC), stirring for 4 hours.  The reaction mixture was then cooled to 
room temperature, and mixed with hexane (11 mL) and EtOAc (5 mL) and washed with 
water (2 x 11 mL), followed by NaHCO3 solution (5 mL), water (4 x 11 mL) and brine (5 
mL), dried over MgSO4, filtered and concentrated in vacuo, afforded a dark brown oil 
that turned out to be not the expected product. 
 
(2S)-4-Nitrophenyl 2-((1,1-dimethylethoxy)methanamido)-3-phenyl propanoate 
(24) 
 
 
 
To N–Boc–L–phenylalanine 22 (6.00 g, 22.6 mmol, 1.0 eq.) in AcOEt (30 mL) were added 
p-nitrophenol 23 (3.15 g, 22.6 mmol, 1.0 eq.) and dicyclohexyl carbodiimide (4.91 g, 
23.8 mmol, 1.1 eq.). The reaction mixture was stirred for 14 hours and then filtered 
through Celite. The resulting clear solution with added hexane (55 mL) was washed 
sequentially with water (30 mL), NaHCO3 solution (30 mL x 3) and brine (30 mL x 3), 
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dried over MgSO4, filtered and concentrated. The resulting solid was azeotroped from 
chloroform yielding 24 as an off white solid (8.50 g, 97%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 1.47 (s, 9 H), 3.24 (d, J=5.9 Hz, 1 H), 4.81 (d, J=1.0 Hz, 
1 H), 5.05 (d, J=1.0 Hz, 1 H), 7.12 - 7.19 (m, 2 H), 7.23 - 7.29 (m, 3 H), 7.32 - 7.40 (m, 2 H), 
8.27 (d, J=9.1 Hz, 2 H). 
The spectroscopic data are consistent with that reported in the literature.57 
 
(3S)-Dimethylsulfoxonium 3-(1,1-dimethylethoxy)methanamido)-2-oxo-4-
phenylbutylide (25) 
 
 
 
A 250 mL round bottom flask was charged with trimethyl sulfoxonium iodide (14.50 g, 
65.8 mmol, 3.0 eq.) and anhydrous THF (66 mL) under nitrogen atmosphere. A solution 
of potassium tert – butoxide (7.40 g, 65.8 mmol, 3.0 eq.) dissolved in 66 mL of 
anhydrous THF was added to first solution. The flask was equipped with a condenser 
and heated to 70 oC for 2 hours. The solution was then cooled to 0 oC. A solution 
prepared by dissolving Boc–L–Phe–4–nitrophenol 24 (8.50 g, 22.0 mmol, 1.0 eq.) in 50 
mL of anhydrous THF was added to the cooled mixture dropwise over 15 min and 
allowed to stir for another hour. Then distilled water was added and stirred further 15 
min and the solution was brought to room temperature. After filtration through Celite, 
filtrate was concentrated in vacuo. The residue was next rinsed with distilled water (45 
mL) and extracted with EtOAc (45 mL and 2 x 20 mL). The organic extract was washed 
with distilled water (2 x 15 mL), NaHCO3 solution (4 x 15 mL) and brine (4 x 15 mL) and 
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concentrated in vacuo. Remaining solid was azeotroped from chloroform and 
evaporated to yield 25 as a light yellow solid (6.55 g; 92%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 1.41 (s, 9 H), 3.00 (d, J=1.0 Hz, 2 H), 3.26 (s, 3 H), 
3.35 (s, 3 H), 4.25 - 4.38 (m, 1 H), 4.27 (s, 1 H), 5.23 (d, J=8.1 Hz, 1 H), 7.13 - 7.33 (m, 5 
H). 
The spectroscopic data are consistent with that reported in the literature.40 
 
(2S)-4-Chloro-3-oxo-1-phenylbutan-2-yl 1,1-dimethylethyl carbamate (26) 
 
 
 
In a 100 mL round bottom flask under nitrogen were placed compound 25 (6.55 g, 19.4 
mmol, 1.0 eq.), 120 mL of THF and a solution of hydrochloric acid in 1,4-dioxane (4.0 M, 
5.6 mL, 22.4 mmol, 1.2 eq.) – was added dropwise over 5 minutes. The mixture was then 
allowed to reflux (70 oC), stirring for 4 hours. After cooling the solution to room 
temperature, it was mixed with hexane (95 mL), and EtOAc (50 mL) and washed with 
water (2 x 100 mL), NaHCO3 solution (50 mL), water (4 x 100 mL) and brine (55 mL). 
After drying organic layer over MgSO4, filtration and concentration, afforded solid was 
recrystallised from minimum of hot hexane and dried to yield 26 as an off-white solid 
(2.76 g, 48%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 1.41 (s, 9 H), 2.94 - 3.17 (m, 2 H), 4.08 (d, J=1.0 Hz, 2 
H), 4.67 (q, J=7.0 Hz, 1 H), 5.05 (d, J=6.6 Hz, 1 H), 7.13 - 7.38 (m, 5 H). 
The spectroscopic data are consistent with that reported in the literature.44 
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(2S,3S)-3,4-Epoxy-1-phenylbutan-2-yl 1,1-dimethylethyl carbamate (27) 
 
 
 
Compound 26 (2.76 g, 9.3 mmol, 1.0 eq.) dissolved in anhydrous ethanol (73 mL) under 
nitrogen was cooled to -78 oC followed by slow addition (20 min) of solution of lithium 
tri-tert-butoxyaluminium hydride in THF (1 M, 19.4 mmol, 19.4 mL, 2.1 eq.). Mixture 
was allowed to stir for 2 hours. After raising the temperature to -20 oC, reaction was 
quenched with Rochelle salt solution (18 mL) and stirred for another 15 min. Resulting 
mixture was then partially evaporated to get two liquid phases of around 10 mL. 
Mixture with extra Rochelle’s salt solution (73 mL) added was extracted with EtOAc 
(180 mL), after which organic layer was washed with water (2 x 70 mL) and brine (70 
mL), dried over MgSO4, filtered and evaporated. Solid was recrystallised from hot 
mixture of EtOAc (3 mL) and hexane (1 mL) to afford desired product 27 as a pale 
yellow solid (2.00 g, 82%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 1.31 (s, 9 H), 2.63 - 2.97 (m, 5 H), 3.62 (br. s., 1 H), 
4.37 (br. s., 1 H), 7.03 - 7.33 (m, 5 H). 
The spectroscopic data are consistent with that reported in the literature.44 
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General procedure A – Epoxide opening 
A round-bottomed flask is charged with a magnetic stirrer bar, epoxide 27 (1.0 eq.), 
lithium perchlorate (1.0 eq.), CH3CN dried over MgSO4 and an amine (5.0 eq. unless 
written differently) and purged with Ar/N2. The solution is magnetically stirred under 
Ar/N2 for 30 hours. Then the reaction is quenched with addition of H2O and transferred 
to a separating funnel. The solution is partitioned with three portions of diethyl ether 
and then organic extract dried over MgSO4 and concentrated in vacuo. The crude 
material is purified by flash column chromatography (various eluent systems) to afford 
the desired N-Boc aminols. 
 
(2S,3R)-3-Hydroxy-1-phenyl-4-(N-(phenylmethyl)amino)butan-2-yl 1,1-
dimethylethyl carbamate (39) 
 
 
 
Using the general procedure A, epoxide 27 (188 mg, 0.71 mmol, 1.0 eq.), lithium 
perchlorate (75 mg, 0.71 mmol, 1.0 eq.) and benzylamine 35 (392 mg, 0.4 mL, 3.60 
mmol, 5.0 eq.) in CH3CN (2 mL) were stirred for 36 hours and then quenched with water. 
The precipitate was rinsed with hexane and water and then collected by filtration giving 
secondary amine 39 as an off white solid (102 mg, 39%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 1.31 (s, 9 H) 2.68 (d, J=4.90 Hz, 2 H) 2.79 - 3.00 (m, 2 
H) 3.38 - 3.50 (m, 2 H) 3.77 (td, J=1.00 Hz, 1 H) 4.63 (d, J=8.29 Hz, 1 H) 7.11 - 7.32 (m, 5 
H). 
The spectroscopic data are consistent with that reported in the literature.50 
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(2S,3R)-3-Hydroxy-4-morpholino-1-phenylbutan-2-yl 1,1-dimethylethyl 
carbamate (40) 
 
 
 
Using the general procedure A, epoxide 27 (188 mg, 0.713 mmol, 1 eq.), lithium 
perchlorate (75 mg, 0.71 mmol, 1.0 eq.) and morpholine 36 (249 mg, 0.25 mL, 2.67 
mmol, 5.0 eq.) in 2 mL of CH3CN were stirred for 48 hours and then quenched with 
water. The precipitate, after addition of a small amount of diethyl ether, was rinsed with 
hexane and water and then collected by filtration, giving 40 (89 mg, 36%). 
mp: 121 – 125 oC;  1H NMR (300 MHz, CDCl3) δ ppm 1.36 (s, 9 H), 2.35 - 2.50 (m, 4 H), 
2.58 - 2.68 (m, 2 H), 2.91 (d, J=4.4 Hz, 1 H), 2.98 (dd, J=1.0 Hz, 1 H), 3.60 - 3.68 (m, 3 H), 
3.69 - 3.75 (m, 3 H), 4.57 (d, J=7.7 Hz, 1 H), 7.21 - 7.34 (m, 5 H);  13C δ: 28.3 (3CH3), 36.3 
(CH2), 53.7 (2CH2), 54.4 (CH), 61.5 (CH2), 67.0 (2CH2), 67.8 (CH), 79.4 (C), 126.3 (CH), 
128.4 (2CH), 129.6 (2CH), 139.5 (C), 155.6 (CH); ES+ MS m/z: 351.2 ([M+H]+) 
[α]D25 and IR tests had not been performed due to lost sample. 
 
(2S,3R)-4-(N,N-Diethylamino)-3-Hydroxy-1-phenylbutan-2-yl 1,1-dimethylethyl 
carbamate (41) 
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Using general procedure A, epoxide 27 (180 mg, 0.68 mmol, 1.0 eq.), lithium 
perchlorate (72 mg, 0.68 mmol, 1.0 eq) and diethylamine 37 (249 mg, 0.35 mL, 3.40 
mmol, 5.0 eq.) in CH3CN (2 mL) were stirred for 30 hours and then quenched with water 
(4 mL). The crashed out solid was rinsed with hexane and water and then collected by 
filtration giving of expecting product 41 (202 mg, 88%). 
 
[α]D25: 65 (c 0.48, CH3OH); mp: 84 – 86 oC; 1H NMR (400 MHz, CDCl3) δ 0.94 (t, J=7.2 
Hz, 6 H), 1.27 (s, 9 H), 2.27 - 2.48 (m, 4 H), 2.48 - 2.61 (m, 2 H), 2.70 - 2.86 (m, 1 H), 2.86 
- 2.99 (m, 1 H), 3.44 (br. s., 1 H), 3.71 (br. s., 1 H), 4.46 (d, J=7.4 Hz, 1 H), 7.07 - 7.29 (m, 5 
H); 13C δ: 12.0 (2CH3), 28.3 (3CH3), 36.4 (CH2), 47.0 (2CH2), 54.5 (CH), 56.4 (CH2), 68.4 
(CH), 79.2 (C), 126.2 (CH), 128.3 (CH), 129.6 (CH), 138.0 (C), 155.5 (C); ES+ MS m/z: 
337.1 ([M+H]+). 
 
(3S,4aS,8aS)-2-((2S,3R)-3-(1,1-Dimethylethoxy)methanamido-2-hydroxy-4-
phenylbutyl)decahydroisoquinoline 3-(N-(1,1-dimethylethyl))carboxamide (44) 
 
 
 
Using the general procedure A, epoxide 27 (200 mg, 0.76 mmol, 1.0 eq.), lithium 
perchlorate (80.85 mg, 0.76 mmol, 1.0 eq.) and 13 (272 mg, 1.14 mmol, 1.5 eq.) in 2 mL 
of CH3CN were stirred for 48 hours and then quenched with water. After triple partition 
with diethyl ether, drying organic layer over MgSO4, and concentration in vacuo, flash 
column chromatography (EtOAc/petroleum ether 1:4) afforded expected 44 as 
transparent/slightly white foam (62 mg, 16%). 
 
1H NMR (400 MHz, CDCl3) δ 1.27 (s, 9 H), 1.28 (s, 9 H), 1.45 (td, J=8.8, 4.5 Hz, 6 H), 1.60 
- 1.64 (m, 1 H), 1.64 - 1.81 (m, 4 H), 1.83 - 1.94 (m, 1 H), 2.15 - 2.26 (m, 2 H), 2.54 (dd, 
 55 
 
J=10.9, 3.2 Hz, 1 H), 2.59 (dd, J=13.4, 6.1 Hz, 1 H), 2.78 - 2.94 (m, 3 H), 3.67 - 3.86 (m, 2 
H), 4.82 (d, J=7.0 Hz, 1 H), 5.86 (s, 1 H), 6.50 (br. s., 1 H), 7.10 - 7.26 (m, 5 H). 
 
The spectroscopic data are consistent with that reported in the literature.47 
 
(2S,3R)-4-(N-Ethanoyl-N-(phenylmethyl)amino)-3-hydroxy-1-phenylbutan-2-yl 
1,1-dimethylethyl carbamate (45) 
 
 
 
Benzylamine derivative compound 39 (130 mg, 0.35 mmol, 1.0 eq.) was added to the 
solution of acetic anhydride (35.62 mg, 32.5 μL, 0.35 mmol, 1.0 eq.) and triethylamine 
(71 mg, 97.5 μL, 0.70 mmol, 2.0 eq.) in 1 mL of CH2Cl2 and stirred for one hour at 0 °C. 
 
Ethyl acetate was added to the solution and washed with aqueous hydrogen chloride 
solution (0.5 M), saturated aqueous sodium bicarbonate solution and brine and then 
dried over MgSO4, filtered and dried in vacuo to afford off yellow solid. 
 
After addition of diethyl ether white solid crushed out and was collected by filtration 
and washed with hexane, affording 45 (64 mg, 44%). 
 
*Acetylation mixture: To a solution of acetic anhydride (2.70 mmol, 27.4 mg, 0.25 mL) 
in DCM (20 mL) was added triethylamine (5.40 mmol, 54.6 mg, 0.75 mL). The solution 
was magnetically stirred and 1 mL taken for this reaction. 
 
[α]D25: - 35 (c 0.51, CH3OH);  mp: 152 – 156 oC; IR: 2971, 2932, 2823, 1604, 1494, 1452, 
1259, 1202 cm-1 ; 1H NMR (300 MHz, CDCl3) δ ppm 1.17 - 1.28 (9 H, s), 2.11 (3 H, s) 
2.65 - 2.83 (1 H, m), 2.89 (1 H, dd, J=13.9, 4.8Hz), 3.30 (1 H, d, J=12.4 Hz), 3.46 - 3.84 (3 
H, m), 4.42 (1 H, d, J=8.4 Hz), 4.51 (1 H, s), 6.97 - 7.43 (10 H, m) 13C δ: 21.7 (CH2), 28.2 
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(3CH3), 36.1 (CH2), 51.1 (CH2), 53.9 (CH2), 71.5 (CH), 73.6 (CH), 79.5 (C), 126.4 (CH), 
127.8 (2CH), 128.4 (2CH), 128.7 (CH), 129.0 (2CH), 129.7 (2CH), 136.0 (C), 137.7 (C), 
155.8 (C), 174.1 (C); ES+ MS m/z: 313.1 ([M+H]+), 335.1 ([M+Na]+);   
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General Procedure B – N-Boc deprotection 
 
A round-bottomed flask is charged with a magnetic stirrer bar, N-Boc 
 aminol (1.0 eq) and 4 M HCl in dioxane (1.5 mL per 100 mg of N-Boc aminol). The 
reaction mixture was stirred for 2 hours under Ar/N2. After completion of reaction 
solvent was evaporated in vacuo, and then co-evaporated two times with CHCl3 (or 
CH2Cl2) and two times with acetonitrile.  
 
(2S,3R)-3-Amino-1-morpholino-4-phenylbutan-2-ol (46) 
 
 
 
Using general procedure B, N-Boc aminol 40 (120 mg, 0.34 mmol) and HCl in dioxane 
(1.8 mL) were stirred under Ar for 90 minutes. Solvent was evaporated, and crude 
material co-evaporated with CHCl3 and CH3CN. Then product was extracted with CH2Cl2 
(10 mL) and aqueous NaOH solution (2 M, 10 mL), dried over MgSO4 and concentrated 
in vacuo, affording 46 (69 mg, 80%). 
 
1H NMR (400 MHz, CDCl3) δ ppm 2.30 - 2.65 (7 H, m), 2.87 (1 H, dd, J=13.4, 4.0 Hz), 
3.09 (1 H, dt, J=9.6, 4.6 Hz), 3.54 - 3.72 (5 H, m), 7.03 - 7.33 (5 H, m). 
The spectroscopic data are consistent with that reported in the literature.58 
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(2S,3R)-Amino-1-(diethylamino)-4-phenylbutan-2-ol (47) 
 
 
 
Using general procedure B, aminol 41 (200 mg, 0.59 mmol) and HCl in dioxane (3 mL) 
were stirred under Ar for 2 hours. Solvent was evaporated, and crude material co-
evaporated with CHCl3 and CH3CN. Then product was extracted with CH2Cl2 (10 mL) and 
aqueous NaOH solution (2 M, 10 mL), dried over MgSO4 and concentrated in vacuo, 
affording 47 (110 mg, 79%).  
 
[α]D25: +85 (c 0.42 , CH3OH); mp: 68 – 72 oC;  IR: 2968, 1716, 1497, 1366, 1259, 1169, 
1015 cm-1; 1H NMR (400 MHz, CDCl3) δ ppm 1.08 (6 H, t, J=7.0 Hz), 2.42 - 2.79 (7 H, m), 
3.01 (1 H, d, J=13.4 Hz), 3.16 (1 H, br. s.), 3.56 (1 H, d, J=5.8 Hz), 7.18 - 7.38 (5 H, m);  13C 
δ: 11.9 (2CH3), 39.8 (CH2), 47.1 (2CH2), 54.9 (CH), 55.9 (CH2), 69.6 (CH), 126.3 (CH), 
128.5 (2CH), 128.9 (2CH), 135.4 (C); ES+ MS m/z: 237.1 ([M+H]+). 
 
(3S)-2-((2S,3R)-Amino-2-hydroxy-phentylbutyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (52) 
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Using general procedure B, N-Boc aminol 44 (30 mg, 0.06 mmol) and 4 M HCl in 1,4-
dioxane (0.45 mL) were stirred under Ar for 2 hours. Solvent was evaporated, and 
crude material co-evaporated with CHCl3 and CH3CN. Such produced product 52 was 
used immediately in next step. 
 
3-Hydroxy-2-methylbenzoic acid (11) 
 
 
 
Concentrated sulfuric acid (5.3 g, 2.6 mL, 56 mmol, 3.7 eq.) was added to the solution of 
water (20 mL) with 3-amino-2-methylbenzoic acid (2.25 g, 15 mmol, 1.0 eq.) and then 
cooled to -10 °C. Sodium nitrite was added gradually (to not exceed 7 °C) to the flask 
and stirred for 30 minutes. Second solution was prepared by adding concentrated 
sulfuric acid (24.5 g, 12 mL, 280 mmol, 18.7 eq.) to distilled water (60 mL) and then 
combined with the first solution. After slow heating the mixture to 80 °C, it was stirring 
for one hour and then cooled again (after no further gas was produced) to the room 
temperature. The reaction mixture was extracted with five portions of EtOAc and then 
organic layer was extracted with NaHCO3 solution. The aqueous extracts were acidified 
to pH 2 by the dropwise addition of HCl, then extracted with a further four measures of 
EtOAc. The organic layers were combined and washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo, affording 11 as an off white solid (1.88 g, 74%). 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 2.35 (s, 3 H), 7.01 (d, J=1.0 Hz, 1 H), 7.11 (t, J=7.9 
Hz, 1 H), 7.23 (d, J=1.0 Hz, 1 H), 9.64 (br. s., 1 H), 12.72 (br. s., 1 H). 
 
The spectroscopic data are consistent with that reported in the literature.1 
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N-((2S,3R)-4-(Diethylamino)-3-hydroxy-1-phenylbutan-2-yl)benzamide 
 
 
A round-bottomed flask was charged with a magnetic stirrer bar, (2S,3R)-amino-1-
(diethylamino)-4-phenylbutan-2-ol 47 (50 mg, 0.21 mmol, 1.0 eq.), benzoyl chloride 
(59.2 mg, 0.05 mL, 0.42 mmo, 2.0 eq.l), triethylamine (0.043 mg, 0.059 mL, 0.42 mmol, 
2.0 eq.) and 1,2-dichloroethane (2 mL). The reaction mixture was stirred for 40 hours 
(first 10 min at 0 oC). After completion of the reaction, ethyl acetate was added to 
mixture and the product was extracted with the aqueous KOH solution (2 M) and brine. 
The organic layers was combined, dried over Mg2SO4 and concentrated in vacuo and 
purified by flash column chromatography (EtOAc/petroleum ether 2:3) to afford the 51 
as an yellow oil (12 mg, 16%). 
 
[α]D25: 15 (c 0.37, CH3OH); IR:2977, 2928, 2481, 1677, 1622, 1417, 1240, 1160, 1009 
cm-1; ES+ MS m/z: 341.1 ([M+H]+), 363.1 ([M+Na]+); 1H NMR (300 MHz, CDCl3) δ ppm 
0.86 (6 H, t, J=7.2 Hz), 2.46 - 2.59 (4 H, m), 2.68 - 2.80 (2 H, m), 2.95 - 3.11 (2 H, m), 4.72 
(1 H, t, J=6.3 Hz), 5.16 (1 H, d, J=4.8 Hz), 7.30 - 7.95 (10 H, m), 8.57 (1 H, d, J=6.8 Hz). 
13C NMR test has not been performed due to lost sample.
 61 
 
 
6.3  BIOLOGICAL TESTING OF NELFINAVIR ANALOGUES 
 
Cell culture: 
THP-1 is a human monocytic leukemia cell line, which was purchased from ECACC 
(Porton Down, UK). THP-1 cells were derived from the peripheral blood of a 1 year old 
male with acute monocytic leukaemia. Cells were cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 10 % foetal calf serum, 2 mM L-1 -glutamine, 100 U/mL 
penicillin and 100 g/mL streptomycin (PAA). They were passaged twice weekly and 
maintained between 2.5-6 x 105 cells/ml at 37 oC and 5% CO2. 
Cell counting: 
Cells were counted using a Neubauer haemacytometer and 0.4% Trypan Blue solution, 
according to the manufacturer’s instructrions (purchased from Sigma-Aldrich). 
Procedure: 20 µL cells were added to 80 µl 0.4% Trypan Blue solution, left for 5 min and 
added to the chamber of the haemacytometer. The average cell count in each corner was 
calculated and the following calculation applied: 
Cell count per ml = average of four corners x 5 (dilution factor) x 104/mL.  
Proliferation assay: 
Proliferation was determined by the MTS assay using the CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (purchased from Promega) according to the 
manufacturer’s instructions.55 
Procedure: THP-1 cells (3 x 104/100µL) were seeded in 96-well plates and left 
untreated or treated with DMSO (vehicle control, Sigma), doxorubicin or compounds 39, 
40, 41, 44, 45 and 47 (with concentrations ranging from 100 pM – 1 mM) in triplicate 
for 72 hr at 37 °C with 5% CO2. Following this, 10 µL MTS assay reagent was added for 4 
hours and the absorbance was measured at 490 nm using the Polarstar Optima 
microplate reader (BMG Labtech). IC50 values were calculated using GraphPad Prism 
Version 5.0 software.  
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Compound 
 
Structure 
 
IC50 
 
Compound 
 
Structure 
 
IC50 
 
 
 
39 
 
 
 
 
34µM 
 
 
 
44 
 
 
 
 
33µM 
 
 
40 
 
 
 
>1mM 
 
 
45 
 
>1mM 
 
 
41 
 
 
 
 
 
37µM 
 
 
47 
 
 
 
2.8µM 
 
Results of MTS assay – IC50 of compounds 39, 40, 41, 44, 45 and 47. 
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